Combination therapy with stavudine, didanosine and hydroxyurea in nucleoside-experienced HIV-1-infected individuals: A preliminary report

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

A pilot study of triple combination therapy with didanosine (2',3'- dideoxyinosine or ddI), stavudine (2',3'-didehydro-2',3'-dideoxythymidine or d4T) plus hydroxyurea was performed in 19 HIV-1-infected individuals previously treated with nucleoside analogues having a mean CD4 cell count of 226 cells/mm3. Complete data were not available for the entire patient population at the time of this preliminary analysis as patients were still undergoing experimental therapy. There was a rapid decrease in viral load to as many as 2.0 log10 copies/ml less than at baseline accompanied by a modest increase in CD4 cells of 30-35 cells/mm3. The reason for the minimal increase in CD4 cells may have been secondary to a relative decrease in total lymphocyte counts due to hydroxyurea. This triple combination was relatively well tolerated and produced a good antiviral effect.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalAntiviral Therapy
Volume2
Issue numberSUPPL.3
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Combination therapy with stavudine, didanosine and hydroxyurea in nucleoside-experienced HIV-1-infected individuals: A preliminary report'. Together they form a unique fingerprint.

Cite this